BAM
PLRX icon

Belpointe Asset Management’s Pliant Therapeutics PLRX Stock Holding History

Belpointe Asset Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-781
Closed -$15.1K – 3823
2022
Q4 		$15.1K Buy
+781
New +$16.3K ﹤0.01% 2391

Other funds holding PLRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Belpointe Asset Management's PLRX Position: Q1 2023 in Review

Belpointe Asset Management sold out of Pliant Therapeutics (PLRX) in Q1 2023, closing a stake of 781 shares — an estimated $15.1K sold.

Belpointe Asset Management first reported a position in PLRX in Q4 2022 and held it in 1 quarter. The position peaked at $15.1K in Q4 2022. 143 funds tracked by Wall St. Rank hold PLRX as of Q1 2023.

  • Belpointe Asset Management reported no remaining Pliant Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 781 Pliant Therapeutics shares in Q1 2023, an estimated $15.1K.
  • Belpointe Asset Management first reported a position in Pliant Therapeutics in Q4 2022 and held it in 1 quarter.
  • Belpointe Asset Management's Pliant Therapeutics position peaked at $15.1K in Q4 2022.
  • 143 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2023.

Based on Belpointe Asset Management's 13F filing for Q1 2023, filed 15 May 2023.